PDS Biotech’s oncology pipeline leverages the Versamune® and Versamune® plus PDS0301 platform technologies in combination with proprietary tumor-specific proteins or peptides (antigens) in the development of targeted cancer immunotherapies.


ProductsIndicationCombinationPCP1P2P3RPARTNER(S)
Oncology
PDS0101 (HPV16) 

Learn more
VERSATILE-002
Recurrent/metastatic HPV16-positive head and neck cancer
KEYTRUDA®
(Standard of Care) 
 merck
Arm 1: Checkpoint inhibitor naïve 1st line treatment
Arm 2: Checkpoint inhibitor refractory 2nd or 3rd line treatment
PDS0101 (HPV16)
PDS0301

Learn more
HPV-positive anal, cervical, head and neck, penile, vaginal, vulvar cancers Bintrafusp alfa

NCI Stacked COLOR   
Arm 1: Checkpoint inhibitor naïve 2nd line treatment
Arm 2: Checkpoint inhibitor refractory 3rd line treatment
PDS0101 (HPV16)

Learn more
IMMUNOCERV
1st line treatment of locally advanced (IB3-IVA) cervical cancer
Chemo-radiation
(Standard of Care)
tobeannounced 
PDS0101 (HPV16) 

Learn more
Pre-metastatic HPV-associated oropharyngeal cancer (OPSCC) KEYTRUDA®
(Standard of Care) 
 merck
Arm 1: PDS0101 monotherapy
Arm 2: PDS0101 + KEYTRUDA
PDS0102
(TARP)
TARP-associated AML, prostate and breast cancers TBD
NCI Stacked COLOR 
PDS0103
(MUC1)
MUC1-associated breast, colon, lung, ovarian and other cancers TBD
NCI Stacked COLOR 
PDS0104
(TRP2)
Melanoma TBD
 
PDS Biotech Funded funded   Partner Co-Funded parfunded